Shares of Aurobindo Pharma climbed 2.7% on Friday, March 24, as Nifty traded lower in the morning session. The stock opened at a price of Rs. 486 per share against the previous close of Rs. 486.15 per share and grew further during the early trading session to touch an intraday high of Rs. 499.50. It was trading at ₹498.10 apiece, up by 2.46%, at 1:05 p.m. on the NSE.
The stock touched a 52-week-high of Rs. 727.90 on March 25, 2022, and a 52-week-low of Rs. 397.20 on February 03, 2023, indicating that at the current level, the stock is trading over 25% above its 52-week low and 31.5% below its 52-week high. The stock has grown almost 6% in the last one month, however, in the last one year, it has yielded a negative return of nearly 31%. In the past five years, the stock has declined over 19%.
In other news, Aurobindo Pharma Foundation (APF), the philanthropic and CSR arm of Aurobindo Pharma Ltd, has donated ₹3.5 crore to build a modern police station in Bachupally, Hyderabad. The state-of-the-art police station, which is a first-of-its-kind in the city, will be inaugurated today by senior representatives from APF and dignitaries from the Police department and the Government of Telangana.
Domestic brokerage ICICI Direct has given a buy call on Aurobindo Pharma with a target price of ₹491.3. According to the analyst, the current market price of Aurobindo Pharma is ₹498 and the target price can be reached within the Intraday period. ICICI Direct has recommended keeping a stop loss of ₹480.8, reported ET.
In the quarter that ended December 2022, the company has reported a consolidated total income of ₹6499.78 crore, a 12.13% increase from the last quarter’s total income of ₹5796.56 crore and a 7.13% increase from the same quarter’s total income of the previous year of ₹6067.21 crore.
Aurobindo Pharma Limited is an India-based pharmaceutical company. The company develops, manufactures, and distributes generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients.
According to a Mintgenie poll, an average of 27 analysts have a ‘Buy’ call on the stock.
